Fixed-dose combinations of antihyperglycaemic therapies were developed to reduce pill burden and improve convenience and adherence in patients with type 2 diabetes (T2DM). OBJECTIVES: To quantify the relative importance of dosing schedules to T2DM patients and to estimate patients’ willingness to pay (WTP) for improvements in dosing schedules. METHODS: Participants were US patients (age ≥18 years) with T2DM who were on oral antihyperglycaemic therapy. Each patient completed a web-enabled, conjoint survey that presented a series of 8 choice questions, each including a pair of hypothetical oral antihyperglycaemic therapy profiles. Each profile was defined by reductions in average glucose, daily-dosing schedule, chance of mild-to-moderate stomach problems, frequency of hypoglycaemia, weight change, incremental treatment-related risk of congestive heart failure (CHF), and out-of-pocket cost. Choice questions were based on predetermined experimental design. Random-parameters logit was used to estimate the relative importance of each attribute and to calculate patients’ WTP for improvements in daily dosing.  RESULTS: Of the 2080 patients invited to participate in the study, 1115 patients completed the survey. Over the ranges of attribute levels in the survey, out-of-pocket cost was the most important attribute. The remaining attributes were ranked in order of importance as: glucose control, hypoglycaemia, chance of mild-to-moderate stomach problems, weight change, incremental chance of CHF, and daily-dosing schedule. On average, patients were willing to pay $35.52 (95% CI: 25.65, 44.89) monthly to move from three pills twice daily to one pill twice daily. Patients were willing to pay $30.72 (95% CI: 21.18, 40.05) monthly to move from three pills twice daily to two pills once daily.  CONCLUSIONS: Although less important than other factors associated with oral antihyperglycaemic therapy, reducing pill burden through reductions in the frequency of dosing or number of pills per dose is of value to T2DM patients.